Intraductal papillary mucinous neoplasm of the biliary tract: a real disease?  by Barton, Joshua G. et al.
ORIGINAL ARTICLE
Intraductal papillary mucinous neoplasm of the biliary tract:
a real disease?
Joshua G. Barton1, David A. Barrett2, Marco A. Maricevich1, Thomas Schnelldorfer1, Christina M. Wood4,
Thomas C. Smyrk2, Todd H. Baron3, Michael G. Sarr1, John H. Donohue1, Michael B. Farnell1, Michael L. Kendrick1,
David M. Nagorney1, Kaye M. Reid Lombardo1 & Florencia G. Que1
Departments of 1Surgery, 2Pathology and 3Gastroenterology, and 4Division of Biostatics, Mayo Clinic, Rochester, MN, USA
Abstracthpb_122 684..691
Background: Despite increasing numbers of reports, biliary tract intraductal papillary mucinous neo-
plasm (BT-IPMN) is not yet recognized as a unique neoplasm. The aim of the present study was to define
the presence of BT-IPMN in a large series of resected biliary neoplasms.
Methods: From May 1994 to December 2006, BT-IPMN cases were identified by reviewing pathology
specimens of all resected cholangiocarcinomas and other biliary neoplasms when cystic, papillary or
mucinous features were cited in pathology reports.
Results: BT-IPMN was identified in 23 out of 253 (9%) specimens using the strict histopathological
criteria of IPMN. The most common presenting symptom was abdominal discomfort which was present
in 15 patients (65%). Only one of the original operative pathology reports used the term IPMN; 16 (70%)
used the terms cystic, mucinous and/or papillary. BT-IPMN was isolated to non-hilar extra-hepatic ducts
in 12 (52%), intra-hepatic ducts in 6 (26%) and hilar extra-hepatic ducts in 5 patients (22%). Carcinoma
was found in association with BT-IPMN in 19 patients (83%); 5-year survival was 38% after resection.
Conclusion: BT-IPMN occurs throughout the intra- and extra-hepatic biliary system and can be iden-
tified readily as a unique neoplasm. Broader acceptance of BT-IPMN as a unique neoplasm may lead to
a better understanding of the pathogenesis of biliary malignancies.
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Introduction
Since the 1960s, a variety of mucin-secreting, papillary and/or
cystic lesions of the intra- and extra-hepatic biliary tract have been
recognized and reported with increasing frequency.1–4 We have
previously reported our experience with such lesions at our insti-
tution.5,6 The pathological similarities between these lesions and
intraductal papillary mucinous neoplasms (IPMN) of the pan-
creas have been suggested.7–9 The recognition of these similarities
coincided with widespread acceptance of the nomenclature of
IPMN for pancreatic lesions in the late 1990s.10 Despite these
reports, biliary tract IPMN (BT-IPMN) is currently neither
broadly nor officially recognized as a unique biliary neoplasm
outside of the pancreas.
We hypothesized that BT-IPMN is a distinct clinicopathological
entity with features analogous to IPMN of the pancreas but with
its own separate identity. The aim of the present study was to
define the presence of BT-IPMN in a large series of resected biliary
neoplasms.
Methods
Between May 1994 and December 2006, all intra- and extra-
hepatic cholangiocarcinomas resected were selected for further
review in order to identify cases of BT-IPMN (n = 223). Slides
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from resected intra-hepatic, extra-hepatic and perihilar biliary
neoplasms other than cholangiocarcinoma were also selected for
further review if the original pathology reports cited findings of
cystic, papillary or mucinous features (n = 22). This methodology
is similar to a study conducted at our institution that identified
patients with pancreatic IPMN prior to use of the IPMN
nomenclature.11
Review of pathology slides was done by two experienced
hepato-pancreato-biliary pathologists at our institution (DB and
TS); discordant pathological reviews were discussed by the two
pathologists, and consensus was reached in the final pathological
diagnosis. BT-IPMN was defined histologically as a mucinous and
papillary neoplasm showing clear origin from biliary epithelium
with solitary or diffuse intraductal growth. We excluded all lesions
originating in the periampullary region of the duodenum or in
the pancreatic ducts (i.e. pancreatic IPMN), lesions in which clear
origin from biliary ducts could not be determined and lesions
with ovarian or mesenchymal stroma. This working definition is
identical to the histological definition for pancreatic IPMN but
mandates that the origin of the lesion be within the biliary tract.
Each case that met the histological criteria for BT-IPMN was
assessed for the presence of a macroscopic intra-luminal lesion
and intra-luminal mucin per international guidelines.12
Each case of biliary tract IPMN was classified as IPMN with
adenoma, moderate dysplasia, carcinoma in situ or invasive carci-
noma according to the guidelines of the World Health Organiza-
tion.13 Patients with invasive carcinoma associated with BT-IPMN
were staged according to guidelines in the American Joint
Committee on Cancer – Cancer Staging Manual, 6th edition.14
Additionally, pre-resection biopsies of patients with BT-IPMN
were reviewed and assessed for the presence of BT-IPMN.
The medical records of patients identified to have BT-IPMN
were reviewed. Demographics, clinical characteristics, pathology
and outcomes were analysed. The Accurint system was used to
augment information regarding death.15 The Accurint system is a
commercially available database containing more than 20 billion
records from 400 sources including dates of death. Data were
summarized using descriptive statistics: median and range for
continuous variables, and count (per cent) for categorical vari-
ables. Survival was analysed using the Kaplan–Meier method. Sta-
tistical analyses were performed using the SAS software package,
v9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Clinical characteristics (Table 1)
BT-IPMN was identified in 23 out of 245 specimens reviewed
(48% men; median age = 68 years; range 31–81 years). BT-IPMN
was identified in 15 out of 223 patients with resected cholangio-
carcinoma reviewed and in 8 out of 22 patients with resected
biliary tract lesions with cystic, papillary or mucinous features
Table 1 Clinical characteristics of patients with BT-IPMN
Demographics n UICC stage (n = 17) n
Age (median years; range) 68 (31–81) Intra-hepatic (n = 3)
Male gender (%) 10 (48) I 1
II 1
Presenting symptoms n (%) IIIA 0
Abdominal discomfort 15 (65) IIIB 0
Jaundice 9 (39) IIIC 1
Weight loss 8 (35) IV 0
Extra-hepatic (n = 14)
Lesion location n (%) IA 8
Extra-hepatic 17 (52) IB 2
Hilar 5 (22) IIA 1
Non-hilar 12 (52) IIB 3
Intra-hepatic 6 (26) III 0
IV 0
Procedure types n (%)
Pancreatoduodenectomy 6 Pre-operative labs (serum) Median (range)
Hepatic & BD resection 6 Total bilirubin (mg/dL) 3.2 (0.4–15.6)
BD resection only 5 Alk. Phos. (U/l) 501 (162–1409)
Hepatic resection 5
Lobectomy 4
Segmentectomy 1
Cholecystectomy 1
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cited in their original pathology reports. Prior to diagnosis, symp-
toms were present for a median of 30 days (range 3 days to 7
years). The most common presenting symptom was abdominal
discomfort occurring in 15 out of 23 patients (65%). Pre-
operative serum total bilirubin concentration and alkaline phos-
phatase activity were available in 15 patients. Serum total bilirubin
was >2.0 mg/dl in 7 patients and serum alkaline phosphatase
activity was increased in all 15 patients.
Pre-operative evaluation included endoscopic retrograde
cholangiography in 14 patients, computed tomography in 12,
ultrasonography in 7, magnetic resonance imaging in 3 and per-
cutaneous transhepatic cholangiography in 2. Characteristic find-
ings on computed tomography (Fig. 1) included the presence of
an intra-luminal lesion originating from the biliary tract with
proximal bile duct dilation.
BT-IPMN was isolated to the extra-hepatic bile ducts in 17
(74%) and the intra-hepatic bile ducts in 6 (26%) patients. Pan-
creatoduodenectomy was performed in six, combined major
hepatic resection and extra-hepatic bile duct resection in six, bile
duct resection in five, hepatic resection in five and cholecystec-
tomy in one patient. Cholecystectomy was performed on one
patient for presumed symptomatic cholelithiasis; an IPMN iso-
lated to the cystic duct was found incidentally. The presence of
large amounts of intra-ductal mucin was noted during the time of
the operation in five patients.
There were two deaths within 60 days of operation. One patient
underwent resection of the common bile duct with Roux-en-Y
hepaticojejunostomy and died 3 days after discharge; this patient’s
post-operative course was complicated by an acute myocardial
infarction and bile leak requiring a 17-day hospitalization. A
second patient underwent a pancreatoduodenectomy for a distal
common bile duct neoplasm and died 2 weeks after discharge; this
patient’s post-operative course was complicated by acute intra-
abdominal haemorrhage post-operatively requiring reoperation,
renal failure and anastomotic leak from the pancreaticojejunos-
tomy requiring a 36-day hospitalization.
Complications occurred in eight patients (35%). Bile leaks
occurred in three and bleeding in the immediate post-operative
period occurred in two patients. One patient each had a leak at
the pancreaticojejunostomy, intra-abdominal abscess, acute renal
failure, pneumonia, pneumothorax, fascial dehiscence, wound
infection and bacteraemia.
Pathology (Tables 2 and 3)
Pre-operative biopsies were performed in 14 patients. Six patients
underwent direct endoscopic biopsy at our institution, and had
material available for repeat analysis. None of the original preop-
erative pathology reports used the term IPMN; 4 (29%) used the
terms ‘cystic’, ‘mucinous’, and/or ‘papillary’. Repeat pathological
review confirmed the presence of BT-IPMN in four out of six
patients with pre-operative biopsies.
Only two of the original pathology reports of the operative
resection specimens used the term IPMN; 16 (70%) used the
terms ‘cystic’, ‘mucinous’ and/or ‘papillary’. The diagnosis of
BT-IPMN was based on the presence of an intraluminal neoplasm
with papillary cyto-architecture; these criteria are in keeping
with the accepted histological definition of pancreatic IPMN10
(Fig. 2b). The neoplastic epithelium was sub-classified as intesti-
nal in 10, pancreatobiliary in 12 and oncocytic in one (Fig. 2c–e,
respectively).
Pre-operative imaging studies and gross descriptions of the
resected tumours indicated that macroscopic intraluminal lesions
were present in 19 patients (83%). Intraluminal mucin was iden-
tifiable upon review of haematoxylin and eosin stains in eight
patients (35%). Using this review for intraluminal mucin on
pathology slides, as well as the original operative reports and gross
pathology descriptions, at total of 17 (74%) unique patients had
evidence of intraluminal mucin.
Reassessment using the WHO classification for pancreatic
IPMN revealed four patients with non-invasive lesions (three with
adenoma and one with moderate dysplasia) and 19 patients with
invasive adenocarcinoma. All invasive adenocarcinomas were
accompanied by carcinoma in situ in the non-invasive component.
None of the 23 patients had only carcinoma in situ without tissue
invasion. Staging information was available for 17 out of 19
patients with invasive malignancy; 3 patients were staged according
A B
Figure 1 Computed tomography depicting an intra-luminal polypoid lesion originating from the biliary tract in extra-hepatic (a) and hilar
(b) locations
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to AJCC Guidelines for intrahepatic bile duct malignancies and 14
according to extrahepatic bile duct malignancies (Table 1).
Recurrence and survival
Out of the 19 patients who had invasive carcinoma in association
with BT-IPMN, 2 patients underwent R1 resections, one of whom
is alive without evidence of recurrence 32 months after resection.
The other patient recurred 8 months post-operatively. Out of the
four patients who did not have invasive carcinoma in association
with BT-IPMN, one had IPMN without dysplasia at the resection
margin and one patient had dysplasia at the resection margin.
There has been no evidence of recurrence or disease-related death
in these patients or in any of the patients without malignancy. At
last follow-up (median = 5.5 years), 9 out of 19 patients with
invasive BT-IPMN had evidence of recurrent carcinoma. The
median survival of all patients with BT-IPMN with invasive carci-
nomas was 2.8 years, and overall 5-year survival was 38% (95% CI
20–72%, Fig. 3).
Discussion
Our findings suggest that BT-IPMN is a lesion that has a mean-
ingful occurrence, is found throughout the intra- and extra-
hepatic biliary tract (including the cystic duct) and can be
identified readily on histopathological review using the criteria
developed by the WHO. In our institution, BT-IPMN represented
7% of all biliary neoplasms resected between 1994 and 2006.
During the same period as this study, 10% of pancreatic resection
specimens at our institution harboured IPMN.
Defining BT-IPMN as a distinct entity has important ramifica-
tions. First, various biliary neoplasms that have been described
previously as adenomas, papillomatosis, adenocarcinoma, cholan-
giocarcinoma, cystic lesions and mucin-secreting lesions could be
defined more clearly and consistently as BT-IPMN. Also, this
delineation may allow study of malignant change in the biliary
epithelium such that, as with pancreatic carcinoma associated
with IPMN, biliary carcinoma arising in BT-IPMN may be recog-
nized to behave differently than the typical cholangiocarcinoma.
The term ‘papillary carcinoma’ enjoys widespread usage in neo-
plasms of the biliary tract. We and others16,17 suggest that papillary
neoplasms in this location, including papillomatosis, are best con-
sidered the biliary counterpart to pancreatic IPMN and represent
a non-invasive neoplasm that may give rise to invasive carcinoma.
Similar to what occurs within the pancreas, as others have pre-
viously recognized,18,19 invasive carcinoma in the setting of
Table 2 Original pathology report diagnoses, the presence of cystic, mucinous and/or papillary features as noted in dictated operative
reports and pathology reports
Patient no. Original pathology
report diagnosis
Reported operative features Original pathology report features Lesion size (cm)
Mucin Cystic Papillary Mucin Cystic Papillary
1 Adenocarcinoma ✓ 1.0
2 Adenocarcinoma 1.7
3 Adenocarcinoma 2.6
4 Adenocarcinoma ✓ ✓ 3.0
5 Adenocarcinoma 4.0
6 Adenocarcinoma 4.8
7 Adenocarcinoma ✓ ✓ 5.0
8 Adenocarcinoma ✓ 7.5
9 Adenocarcinoma 11.0
10 Adenocarcinoma ✓ ✓ Not available
11 Adenocarcinoma ✓ 4.0
12 Adenocarcinoma ✓ ✓ 2.3
13 Biliary papillomatosis ✓ ✓ ✓ 4.0
14 Cholangiocarcinoma ✓ 2.0
15 Cholangiocarcinoma ✓ 2.0
16 Cholangiocarcinoma ✓ ✓ 2.8
17 Cholangiocarcinoma ✓ ✓ 3.5
18 Cystadenoma ✓ ✓ ✓ ✓ 1.6
19 Cystadenoma ✓ ✓ 1.8
20 Cystic neoplasm ✓ ✓ ✓ 15.0
21 Cystic neoplasm ✓ ✓ ✓ ✓ ✓ 7.5
22 IPMN with carcinoma ✓ ✓ 2.0
23 IPMN with carcinoma ✓ 2.3
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Table 3 Results of features noted on review of original imaging studies, gross pathology reports and pathology slides
Patient no. Macro intraluminal lesion Intraluminal mucin Lesion mocation IPMN type
1 ✓ Distal extra-heptic Invasive carcinoma
2 ✓ ✓ Distal extra-heptic Invasive carcinoma
3 ✓ ✓ Distal extra-heptic Invasive carcinoma
4 Distal extra-heptic Invasive carcinoma
5 ✓ Intra-hepatic Invasive carcinoma
6 Distal extra-heptic Invasive carcinoma
7 ✓ Distal extra-heptic Invasive carcinoma
8 ✓ ✓ Hilar extra-hepatic Invasive carcinoma
9 Intra-hepatic Invasive carcinoma
10 ✓ Hilar extra-hepatic Invasive carcinoma
11 ✓ Distal extra-heptic Invasive carcinoma
12 ✓ Distal extra-heptic Invasive carcinoma
13 ✓ ✓ Hilar extra-hepatic Invasive carcinoma
14 Hilar extra-hepatic Invasive carcinoma
15 ✓ Distal extra-heptic Invasive carcinoma
16 ✓ Hilar extra-hepatic Invasive carcinoma
17 ✓ ✓ Intra-hepatic Invasive carcinoma
18 ✓ Distal extra-heptic Adenoma
19 ✓ ✓ Intra-hepatic Invasive carcinoma
20 ✓ Intra-hepatic Adenoma
21 ✓ ✓ Intra-hepatic Adenoma
22 ✓ ✓ Distal extra-heptic Invasive carcinoma
23 ✓ Distal extra-heptic Dysplasia
IPMN, intraductal papillary mucinous neoplasm.
A
B C
D E
Figure 2 Photograph A shows a distal common bile duct intraductal papillary mucinous neoplasm (IPMN) with characteristic gross polypoid
features. Photographs B–E show haematoxylin and eosin stains of different biliary tract (BT)-IPMNs with papillary cytoarchitecture within the
benign portion (b), intestinal epithelium (c), pancreatobiliary epithelium (d) and oncocytic epithelium (e)
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BT-IPMN resembles typical adenocarcinoma often with muci-
nous (colloid) morphology but is rarely papillary. Although inva-
sive papillary structures can be seen histologically,18 this very
rarely occurs within the biliary tract in our experience and was not
found in any patient in our study. Along those lines, invasive
papillary structures can occur theoretically without the presence
of IPMN. Thus, our definition of BT-IPMN is not a wholesale
reclassification of papillary carcinoma. It is likely, however, that a
significant number of lesions that have been previously described
as papillary carcinoma are typical sclerotic adenocarcinoma with
adjoining IPMN; in this setting, ‘papillary’ refers to what we feel
would be better described as IPMN. Whether the lack of papillary
changes in the invasive component is secondary to the malignant
phenotype of cholangiocytes or is in response to the extracellular
matrix is unknown.
During the course of this study, not every cystic lesion of the
bile duct reviewed was reclassified as IPMN. Similar to cystic
lesions of the pancreas, the differentiation between BT-IPMN and
cystadenoma or cystadenocarcinoma of the biliary tract was
dependent on the presence of mesenchymal stroma in the latter.
The original diagnosis of cystadenoma or cystic biliary neoplasm
in three patients in this study highlights the potential need for
clarification of certain unusual cystic biliary tract neoplasms
similar to that which has evolved for cystic pancreatic lesions,
leading to the adoption of the WHO classification for IPMN.
Thus, all ‘biliary’ cystic, mucinous or papillary neoplasms do not
necessarily present as BT-IPMN, although 36% of such neoplasms
in our series proved to be BT-IPMN.
Similarities between biliary and pancreatic IPMN can be
explained given the shared embryological development of the bile
duct and the main pancreatic duct from the hepatic diverticulum
in the foregut mesoderm,20 but important differences may exist.
As in our study, when reviewing the historical presence of
pancreatic IPMN at our institution, Tollefson et al. found that
abdominal discomfort was the most common presenting symp-
tom.11 In contrast, Tollefson et al. reported jaundice in 62% of
pancreatic IPMN patients compared with 39% in our study. This
difference is likely as a result of the various sites of origin of
BT-IPMN, from within the liver itself to the distal common bile
duct, thus producing a constellation of symptoms more similar to
cholangiocarcinoma.21 Additionally, the frequency of invasive car-
cinoma in patients with resected BT-IPMN appears to be greater
than in patients with resected pancreatic IPMN. In our study, 83%
of patients with resected BT-IPMN had invasive carcinoma com-
pared with only 30% of patients with resected pancreatic IPMN at
our institution.19
Other potential differences between BT-IPMN and its pancre-
atic counterpart are worth noting. Diffuse involvement of the
pancreas is often seen with pancreatic IPMN. Interestingly, we
found evidence of BT-IPMN occurring in a diffuse manner in
only one patient who was originally diagnosed with papillomato-
sis. Additionally, pancreatic IPMN is known to recur after resec-
tion even in benign cases.19,22 We found no evidence of recurrent
BT-IPMN-adenoma after resection in our cohort. Also, gross cystic
dilatation was noted in the original operative reports in only six
patients in our study: three had intra-hepatic lesions, two had
extra-hepatic distal lesions and one had an extra-hepatic hilar
lesion. Although gross cystic dilatation is often associated with
pancreatic IPMN, this feature is highly variable and is not a pre-
requisite for diagnosis of pancreatic IPMN according to the WHO
criteria.13 Whether the apparent differences between BT-IPMN
and its pancreatic counterpart are because of different tumour
biology or are a product of the difference between the physical
structures of the biliary and pancreatic ductal systems is unclear.
Zen et al. demonstrated that pancreatic IPMN overall has lower
CK-20 expression and a higher frequency of gastric cell-type
tumours than BT-IPMN.17 This difference is less apparent,
however, when excluding branch-duct IPMNs of the pancreas
which express rarely CK-20 and are commonly gastric cell-type
tumours. It is therefore plausible that BT-IPMNs are more closely
related to main duct IPMNs of the pancreas. In any case, these
features highlight the heterogeneous nature of all IPMNs irrespec-
tive of the biliary counterpart.
International consensus guidelines define IPMN as a ‘grossly
visible, non-invasive, mucin-producing, predominantly papillary
or, rarely flat, epithelial neoplasm’.12 These guidelines were created
in order to clearly delineate IPMN from pancreatic intraepithelial
neoplasm (PanIN) which can be impossible to differentiate by
microscopic evaluation of routine haematoxylin and eosin stains
only. In fact, the presence of a macroscopic intraluminal lesion
and visible mucin on the surface of the tumour are the main
characteristics differentiating IPMN and PanIN. In our study,
macroscopic intra-luminal lesions were present in 83% of patients
with BT-IPMN. Although the epithelium of the lesions in each
patient found to have BT-IPMN in this study was mucinous, the
presence of intraluminal mucin was variable which is similar to
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Figure 3 Kaplan–Meier curve depicting the survival for 19 patients
who had carcinoma in association with BT-IPMN. Survival was 77%
at 1 year (n = 13; 95% CI 60–100%), 46% at 3 years (n = 7; 95% CI
27–78%) and 38% at 5 years (n = 4; 95% CI 20–72%)
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findings of other studies.17,23 We found documentation or evi-
dence on review of pathology slides of visible intraluminal mucin
in 74% of patients with BT-IPMN in our study. It is possible that
intraluminal mucin was present in more patients but the fixation
and staining process makes the detection of mucin unreliable and
is a significant limitation of this study. In any case, as with cystic
dilatation, the presence of mucin is considered to be variable even
in pancreatic IPMN.12,13 As Adsay suggests, mucin production and
even cystic dilatation may be dependent on ‘the location of the
primary process and subsequent mechanical changes in the
ducts’.24
In our study, all the patients with BT-IPMN clearly met the
histological criteria for IPMN. Although it is quite feasible that a
minority of these patients truly did not have the macroscopic
criteria for IPMN, we are hampered by the retrospective nature of
this study as such features are not uniformly documented and
re-evaluation of gross specimens is impossible. Evaluation of gross
specimens is the best opportunity for assessing macroscopic fea-
tures. At most, the minority of patients in this study who truly do
not meet the macroscopic criteria for IPMN had lesions which
might be better described as biliary intra-epithelial neoplasms
(BilIN). This idea only further supports the concept that these
biliary lesions are the counterpart of pancreatic ductal lesions and
may share similar pathogenesis. In fact, as a result of guidelines
developed in Asia,25 international consensus guidelines that
include the experiences of western clinicians were developed for
the diagnosis of BilIN.23 One of the contentions of this inter-
observer group is that BilIN and BT-IPMN, or ‘biliary IPN’ as they
refer to it, are major precursor lesions associated with the devel-
opment of cholangiocarcinoma. Inter-observer guidelines for
BT-IPMN have been proposed but are not yet completed.
Our findings suggest that patients with BT-IPMN may have a
survival similar to its pancreatic counterpart. A recent study at our
institution19 indicates that survival after resection of invasive pan-
creatic carcinoma in the setting of IPMN is similar to survival
after curative resection of pancreatic ductal adenocarcinoma
without IPMN when compared stage for stage (31% vs. 24%
survival at 5 years, respectively). Interestingly, the survival for
invasive pancreatic carcinoma associated with IPMN is similar to
the survival at 5 years (38%) for patients with invasive carcinoma
associated with BT-IPMN after resection in our study. Although
the limited number of patients (n = 23) available for analysis in
our study prevents an absolute conclusion, these trends in our
data warrant further investigation.
Comparing the survival of patients with invasive carcinoma in
association with BT-IPMN to patients with cholangiocarcinoma
alone may be more revealing and useful than comparing
BT-IPMN with IPMN of the pancreas. Survival at 5 years for
patients with resected cholangiocarcinoma varies from 8–30%
depending both on location of the lesion and the particular study
reviewed.26–28 Studies at our institution found that 5-year survival
was 26% for patients with resected hilar cholangiocarcinoma28
and 20% for patients with resected distal common bile duct cho-
langiocarcinoma.29 The small size of our study prevents broader
conclusions, but the overall 5-year survival of 38% in our study
suggests better survival for patients with carcinoma associated
with BT-IPMN.
As previously shown,30–33 depth of invasion is an important
predictor of survival after resection of cholangiocarcinoma. This
may play a role in the greater survival seen in our study for
patients with BT-IPMN and may not reflect an intrinsic difference
in tumour biology. Interestingly, Albores-Saavedra et al. suggest
that, in contrast to typical cholangiocarcinoma, invasive papillary
cholangiocarcinoma (which we would consider to be invasive
BT-IPMN) grows towards the bile duct lumen prior to invading
the bile duct wall.30 We did not assess depth of invasion for the
patients with BT-IPMN in this study or patients with typical
cholangiocarcinoma and cannot comment on how the depth of
invasion may play a role in our cohort.
Two original pathology reports of patients who underwent
resection of a BT-IPMN used the term ‘IPMN’. These patients who
underwent resection after nomenclature for IPMN of the pan-
creas had been adopted at our institution; nine other patients
underwent resection after this time point as well but were not
diagnosed originally with IPMN. This observation highlights both
the need for an awareness of these histological findings as a dis-
tinct entity and consideration for BT-IPMN as the appropriate
nomenclature for these lesions within the biliary tract.
Our study has several limitations not discussed above. First,
although our study suggests that BT-IPMN is a distinct patho-
logical entity and is clinically meaningful, we only reviewed the
pathology of resected lesions. These findings require further
studies to confirm the presence of this entity outside of resected
specimens and to establish accurately the actual incidence and
prevalence of BT-IPMN. We maintain that BT-IPMN exists as a
unique neoplasm and is often unrecognized, similar to the story
with IPMN of the pancreas. Second, our data on recurrence are
not as robust as survival data; a large proportion of our patient
population is referred from distant locations and thus seeks
long-term follow-up elsewhere. More complete follow-up
imaging of BT-IPMN will not only provide better data on pat-
terns of failure, but also on progression of adenoma to invasion
and development of other extra-biliary neoplasms as occurs in
pancreatic IPMN.34 In conclusion, we maintain that BT-IPMN is
an identifiable neoplasm that occurs with meaningful frequency
in resected biliary tract neoplasms. We provide strong
histopathological data to establish this neoplasm as a unique
clinicopathologic entity. Similar to pancreatic IPMN, universal
acceptance of BT-IPMN as a unique neoplastic spectrum may
lead to a better understanding of the pathogenesis of biliary
malignancies. This concept may modify our approach to selected
biliary tract malignancies which could result in improved
survival.
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